Palvella Therapeutics Inc... (PVLA)
Palvella Therapeutics Inc. (PVLA) Stock Price, Analysis & Data
| Bid | 111.17 |
| Market Cap | 2.26B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.7M |
| Beta | n/a |
| EPS (ttm) | -4.85 |
| PE Ratio (ttm) | n/a |
| Forward PE | -20.92 |
| P/B (ttm) | 10.41 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 195.41 |
| Volume | 127,849 |
| Avg. Volume (20D) | 253,953 |
| Open | 157.51 |
| Previous Close | 154.30 |
| Day's Range | 152.99 - 157.99 |
| 52-Week Range | 41.71 - 161.38 |
| Analyst | Strong Buy |
| Price Target | 232 (47.88%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformation...
Financial Performance
In 2025, Palvella Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -41.72M, an increase of 139.27%.
Financial StatementsAnalyst Forecast
According to 15 analyst ratings, the average rating for PVLA stock is "Strong Buy". The 12-month stock price forecast is 232, which is upside of 47.88% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
